series-b
Stage
1
Investors
About
Minoryx is a clinical-stage biotechnology company developing therapies for orphan central nervous system (CNS) diseases. Its lead program, MIN-102, is in clinical trials for X-linked Adrenoleukodystrophy and Friedreich’s Ataxia, and the company operates in Spain (Mataró, Barcelona) and Belgium (Charleroi Brussels South Biopark).
Explore Minoryx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.